Guggenheim analyst Swati Kumar reiterated a Buy rating and boosted its price target on Endo Pharmaceuticals Holdings Inc (NASDAQ: ENDP) ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE